Spots Global Cancer Trial Database for Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Official Title: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Study ID: NCT03906331
Interventions
Study Description
Brief Summary: Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed Description: N/A for expanded access
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Treatment Centers of America, Goodyear, Arizona, United States
Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Irvine Medical Center, Orange, California, United States
University of California - San Diego, San Diego, California, United States
Univ of California San Francisco, San Francisco, California, United States
Memorial Cancer Institute, Hollywood, Florida, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Florida Hospital, Orlando, Florida, United States
Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States
University Cancer and Blood Center, Athens, Georgia, United States
Emory University, Atlanta, Georgia, United States
University of Chicago Medicine-Comprehensive Cancer Center, Chicago, Illinois, United States
Cancer Treatment Centers of America, Zion, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Ohio State University Medical Center, Columbus, Ohio, United States
Cancer Treatment Centers of America, Tulsa, Oklahoma, United States
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States
NSW Health - Sydney Local Health District, Camperdown, New South Wales, Australia
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
Queensland Health - Metro North Hospital and Health Service, Chermside, Queensland, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, France
AP-HM, Marseille, , France
Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
Charité Campus Virchow-Klinikum, Berlin, , Germany
Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Soroka Medical Center - Pediatric Outpatient Clinic, Beer-Sheva, , Israel
Istituto Nazionale dei Tumori, Milano, Lombardie, Italy
Azienda Ospedaliero Universitaria Pisana, Pisa, PI, Italy
ASST Grande Ospedale Metropolitano Niguarda Comitato Etico Milano Area C, Milano, , Italy
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Tottori University Hospital, Yonago, Tottori, Japan
Osaka City General Hospital, Osaka, , Japan
University of Auckland, Auckland, , New Zealand
Centrum Onkologii Instytut im Marii Curie w Warszawie, Warszawa, , Poland
National Cancer Centre Singapore, Singapore, Central Singapore, Singapore
Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain
Hospital Madrid Norte Sanchinarro, Madrid, , Spain
Kantonsspital Luzern, Luzern 16, Luzern, Switzerland
Contact Details
Name: Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
